Studies differ on cost-effectiveness of PCSK9 inhibitors

Two updated cost-effectiveness analyses published in the Journal of the American Medical Association and JAMA Cardiology based on data from the Phase III FOURIER cardiovascular outcomes trial (CVOT) suggest that the price of PCSK9 inhibitors, including Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN), would need to be reduced to meet cost-effective thresholds.

Data from FOURIER released in March showed that Repatha significantly reduced the risk of myocardial infarction (MI) and stroke, but failed to cut the risk of cardiovascular death (see BioCentury Extra, March 17)...